Supplemental material
Leukemia & Lymphoma
Volume 64, 2023 - Issue 5
Open access
2,334
Views
1
CrossRef citations to date
0
Altmetric
Original Articles
Patient-reported outcomes from the phase 3 ADMIRAL trial in patients with FLT3-mutated relapsed/refractory AML
Ellen K. Ritchiea Department of Medicine, Weill Cornell Medicine, New York City, NY, USACorrespondence[email protected]
View further author information
, View further author information
David Cellab Department of Medical Social Sciences, Northwestern University, Feinberg School of Medicine, Chicago, IL, USAView further author information
, Francesco Fabbianoc Department of Hematology, Azienda Ospedaliera Ospedali Riuniti Villa Sofia-Cervello, Palermo, ItalyView further author information
, Arnaud Pigneuxd Department of Hematology and Cell Therapy, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, FranceView further author information
, Yoshinobu Kandae Division of Hematology, Jichi Medical University, Tochigi, JapanView further author information
, Cristina Ivanescuf Patient Centered Solutions, IQVIA, Amsterdam, NetherlandsView further author information
, Bhavik J. Pandyag Medical Affairs, Astellas Pharma, Inc., Northbrook, IL, USAView further author information
& Manasee V. Shahg Medical Affairs, Astellas Pharma, Inc., Northbrook, IL, USAView further author information
show all
Pages 938-950
|
Received 01 Sep 2022, Accepted 25 Feb 2023, Published online: 05 Apr 2023
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.